Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015

Artola, Sara; García-Moll, Xavier; Uría, Estefany; López-Martínez, Noemí; Palomino, Rosa; Martín, Virginia

doi:10.1136/bmjdrc-2019-001130

Cited by 11 publications

(6 citation statements)

References 48 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review by the Health Technologies Assessment Agency of Spain confirmed that the major components of the costs of T2DM were hospitalization (10-67%) and costs of medication for T2DM complications (14-33%) [81], results also reported by the previously mentioned Mata-Cases et al study in Catalonia [43]. Further, a recent study demonstrated that the length of hospital stay was longer for patients with T2DM, compared with patients without diabetes, for non-fatal acute myocardial infarction and unstable angina, resulting in higher hospitalization costs [82].…”

Section: Discussionsupporting

confidence: 54%

Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Introduction: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with type 2 diabetes mellitus (T2DM). The objectives of this systematic literature review were to identify and synthesize published data describing the epidemiology and mortality of CVD in the T2DM population and the associated economic burden. Methods: We conducted a systematic review searching the PubMed and MEDES databases from 2009 to 2019 using predefined selection criteria. Peer-reviewed observational studies reporting primary or secondary data on CVD prevalence, incidence, mortality, resource use and costs in patients with T2DM in Spain, written in English and Spanish, were included. Data were tabulated and summarized descriptively. Results: Of 706 articles identified, 52 were included in the review. Most studies were based on data from hospital discharge databases and registries. The reported prevalence of CVD among patients with T2DM ranged from 6.9 to 40.8%. The prevalence of coronary heart disease ranged from 4.7 to 37%, stroke from 3.5 to 19.6%, peripheral artery disease from 2.5 to 13.0%, and heart failure from 4.3 to 20.1%. Inhospital CVD mortality rates ranged from 5.6 to 10.8%. Direct costs due to CVD in hospitalized patients with T2DM were increased ([ 50%) compared with patients without CVD. No studies analysed indirect costs of CVD in patients with T2DM. Conclusions: The burden of CVD among patients with T2DM, combined with the elevated costs of care, highlights the importance of early prevention as part of integrated management of the disease to improve clinical and economic outcomes.

show abstract

Section: Discussionsupporting

confidence: 54%

Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A statistical power analysis considering the proportion of patients with T2D suffering from CVD in our study population (35.6%) was performed. The scientific literature corroborates this proportion describing a mean prevalence of 32.2% of CVD in patients with T2D worldwide ( 20 , 21 ). Considering our sample comprises 46 T2D patients with CVD and 83 T2D patients without prevalent CVD our statistical power is >85% (e.g., 87.7%).…”

Section: Methodssupporting

confidence: 52%

Exploring the role of osteoglycin in type 2 diabetes: implications for insulin resistance and vascular pathophysiology

González-Salvatierra,

García-Fontana,

Martínez-Heredia

et al. 2023

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Osteoglycin, a fundamental proteoglycan within the vascular extracellular matrix, is expressed in vascular smooth muscle cells (VSMCs). Type 2 diabetes (T2D) is associated with cardiovascular disease (CVD) but the role of osteoglycin in the development of CVD is controversial to date. Therefore, our aims are to determine and compare the level of osteoglycin in T2D patients with/without CVD versus control subjects both at serum and vascular tissue, and to analyze in vitro the role of osteoglycin in VSMCs under calcified conditions . For this , serum osteoglycin levels were determined by ELISA in 117 controls and 129 T2D patients (46 with CVD and 83 without CVD), revealing a significant increase in T2D patients compared to controls. Osteoglycin level was not estimator of CVD but correlated with markers of insulin resistance (triglycerides and triglycerides/ high-density lipoprotein cholesterol index) in T2D patients. At the vascular level, osteoglycin expression was assessed by RT-qPCR and immunohistochemistry, and no significant differences were observed between calcified arteries from T2D patients and non-calcified arteries from controls. In vitro experiments using VSMCs (mock and overexpressing osteoglycin) under calcifying conditions were performed to analyze the osteoglycin function. The overexpression of osteoglycin in VMSCs under calcifying conditions revealed an increase of cell proliferation without effect on apoptosis, and an up-regulation of the expression of autotaxin ( ATX) involved in inflammatory processes. In conclusion, osteoglycin could play a role in glycemic homeostasis, being a potential biomarker of insulin resistance in T2D patients. Furthermore, osteoglycin could indirectly participate in the development of atherosclerosis through its regulatory effect on ATX and by proliferating VSMCs.

show abstract

“…In the same year, five million deaths were attributed to DM, and worldwide 850 billion US dollars were spent on managing the disease [ 2 ]. The costs arising from DM are mainly due to the associated complications, chief among which are ischemic heart disease, stroke, diabetic foot and diabetic nephropathy [ 3 , 4 ]. Socioeconomic factors such as gender, age, education, type of health insurance and the time of evolution since diagnosis are significantly associated with disease outcomes [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Validation of living with chronic illness scale in a type 2 diabetes mellitus population

Caro‐Bautista

Rodríguez‐Blázquez

Pérez-Manchón

et al. 2021

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background Worldwide, type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic diseases and one of those producing greatest impact on patients’ day-to-day quality of life. Our study aim is to validate the “Living with Chronic Illness Scale” for a Spanish-speaking T2DM population. Methods In this observational, international, cross-sectional study, 582 persons with T2DM were recruited in primary care and outpatient hospital consultations, in Spain and Colombia, during the period from May 2018 to June 2019. The properties analysed were feasibility/acceptability, internal consistency, reliability, precision and (structural) content-construct validity including confirmatory factor analysis. The COSMIN checklist was used to assess the methodological/psychometric quality of the instrument. Results The scale had an adequate internal consistency and test retest reliability (Cronbach’s alpha = 0.90; intraclass correlation coefficient = 0.96, respectively). In addition, the instrument is precise (standard error of measurement = 3.34, with values < ½SD = 8.52) and correlates positively with social support (DUFSS) (rs = 0.56), quality of life (WHOQOL-BREF) (rs = 0.51–0.30) and ssatisfaction with life (SLS-6) (rs = 0.50–0.38). The original 26-items version of the scale did not support totally the confirmatory factor analysis. The COSMIN checklist is favourable for all the properties analysed, although weaknesses are detected for structural validity. Conclusions The LW-CI-T2DM is a valid, reliable and accurate instrument for use in clinical practice to determine how a person’s life is affected by the presence of diabetes. This instrument correlates well with the associated constructs of social support, quality of life and satisfaction. Additional research is needed to determine how well the questionnaire structure performs when robust factor analysis methods are applied.

show abstract

Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015

Cited by 11 publications

References 48 publications

Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review

Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review

Exploring the role of osteoglycin in type 2 diabetes: implications for insulin resistance and vascular pathophysiology

Validation of living with chronic illness scale in a type 2 diabetes mellitus population

Contact Info

Product

Resources

About